PharmAla supplies Johns Hopkins with drugs for clinical trial Page 1

TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla“ or the “Pursue”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development and manufacturing of LaNeo MDMA and novel derivatives of MDMA (MDXX class molecules), is proud to announce that it has signed a contract to be the supplier of MDMA for a clinical trial at Johns Hopkins Medicine.

“We look forward to continuing to provide exceptional service and robust investigational medicinal products to researchers in the U.S. and around the world,” said Nicholas Kadysh, CEO of PharmAla Biotech. “Over the past month, we have spoken with many researchers and we believe that only PharmAla is able to meet the need for GMP MDMA that meets the quality standards of regulatory agencies like the FDA.”